221 related articles for article (PubMed ID: 34059720)
1. A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin.
Watanabe Y; Suzuki D; Kuribayashi N; Uchida D; Kato M; Ohashi H; Nagayama D; Yamaguchi T; Ohira M; Saiki A; Tatsuno I
Sci Rep; 2021 May; 11(1):11350. PubMed ID: 34059720
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
[TBL] [Abstract][Full Text] [Related]
3. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
[TBL] [Abstract][Full Text] [Related]
4. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.
Watanabe Y; Kuribayashi N; Uchida D; Suzuki D; Kato M; Nagayama D; Ohashi H; Ohira M; Saiki A; Tatsuno I
Diabetes Ther; 2019 Feb; 10(1):311-321. PubMed ID: 30574667
[TBL] [Abstract][Full Text] [Related]
5. Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Bouchi R; Sonoda N; Itoh J; Ono Y; Fukuda T; Takeuchi T; Kishimoto J; Yamada T; Ogawa Y
Endocr J; 2021 Mar; 68(3):329-343. PubMed ID: 33390421
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus.
Kohlmorgen C; Gerfer S; Feldmann K; Twarock S; Hartwig S; Lehr S; Klier M; Krüger I; Helten C; Keul P; Kahl S; Polzin A; Elvers M; Flögel U; Kelm M; Levkau B; Roden M; Fischer JW; Grandoch M
Diabetologia; 2021 Aug; 64(8):1834-1849. PubMed ID: 34131781
[TBL] [Abstract][Full Text] [Related]
7. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes.
van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH
Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432
[TBL] [Abstract][Full Text] [Related]
8. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Yamakage H; Tanaka M; Inoue T; Odori S; Kusakabe T; Satoh-Asahara N
J Diabetes Investig; 2020 May; 11(3):653-661. PubMed ID: 31721467
[TBL] [Abstract][Full Text] [Related]
9. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial.
Karg MV; Bosch A; Kannenkeril D; Striepe K; Ott C; Schneider MP; Boemke-Zelch F; Linz P; Nagel AM; Titze J; Uder M; Schmieder RE
Cardiovasc Diabetol; 2018 Jan; 17(1):5. PubMed ID: 29301520
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus.
Kurinami N; Sugiyama S; Yoshida A; Hieshima K; Miyamoto F; Kajiwara K; Jinnouch K; Jinnouchi T; Jinnouchi H
Diabetes Res Clin Pract; 2018 Aug; 142():254-263. PubMed ID: 29859912
[TBL] [Abstract][Full Text] [Related]
11. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
Shin Y; Choi H; Lim S
Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Atheroscler Thromb; 2018 Jun; 25(6):467-476. PubMed ID: 29225209
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.
Daniele G; Xiong J; Solis-Herrera C; Merovci A; Eldor R; Tripathy D; DeFronzo RA; Norton L; Abdul-Ghani M
Diabetes Care; 2016 Nov; 39(11):2036-2041. PubMed ID: 27561923
[TBL] [Abstract][Full Text] [Related]
16. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
Bailey CJ; Del Prato S; Wei C; Reyner D; Saraiva G
Diabetes Obes Metab; 2019 Nov; 21(11):2564-2569. PubMed ID: 31364269
[TBL] [Abstract][Full Text] [Related]
17. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
18. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
20. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
